Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...

RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

The pharmaceutical sector continues to attract investor attention, with recent clinical developments highlighting the industry’s innovation potential. Moderna (MRNA) emerged as the top-performing ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. Moderna Inc. (NASDAQ:MRNA) was one of the top performers on Tuesday. Moderna rebounded by 17.02 percent on Tuesday ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

A global international trial of an mRNA vaccine against norovirus is getting underway with the aim of reducing the health burden caused by the infamous “winter vomiting” bug. The trial has been ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...